High-risk Non-muscle Invasive Bladder Cancer research hub
5 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is looking into a new treatment for a type of bladder cancer called high-risk non-muscle invasive bladder cancer. It combines a drug called pembrolizumab with an existing treatment, BCG, to see if it works better and is safe.
United States · Australia · Austria - recruitingPhase III
A randomised Phase III trial to assess whether radiotherapy with radiosensitisers is beneficial in patients with high-risk non-muscle invasive bladder cancer when compared with the standard of care treatment, Bacillus Calmette-Guerin
This study compares two treatments for high-risk bladder cancer that hasn't spread to the muscle: standard treatment (BCG immunotherapy) versus a new approach combining radiotherapy with special drugs. We want to see if the new approach works better to prevent cancer recurrence or progression.
United Kingdom · England - not yet recruitingPHASE3
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
This study compares two ways to treat high-risk bladder cancer that hasn't spread: standard BCG therapy (a medicine put into the bladder) versus a combination of radiotherapy and a special drug to make it work better. It aims to find a more effective and reliable treatment.
United Kingdom - recruitingPhase III
Is Gem-Doce an alternative to BCG treatment for people with early bladder cancer?
This study compares a new treatment called Gem-Doce with the usual BCG treatment for early bladder cancer. It aims to see if Gem-Doce works as well as BCG but with fewer side effects, offering a potentially better option for patients.
United Kingdom - recruitingPhase III
A phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of TAR-210 erdafitinib intravesical delivery system versus investigator’s choice of intravesical chemotherapy in participants with high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations who had received intravesical Bacillus Calmette-Guérin (BCG)
This study looks at a new bladder cancer treatment called TAR-210 for people with high-risk, early-stage bladder cancer that hasn't spread to the muscle. It compares TAR-210 to standard chemotherapy to see which works best and is safest. You might be able to join if you've had a type of chemotherapy called BCG.
United Kingdom · Argentina · Belgium